| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 22, 2020 | Illumina to acquire early cancer detection startup Grail for $8B | Grail plans to launch Galleri, a lab-developed test to detect cancers early in the blood, commercially next year. The company says the test has greater than 99% specificity and 93% tissue-of-origin accuracy to detect at least 50 cancers, wi... |
| Sep 21, 2020 | Ally Bridge Portfolio News – Illumina to Acquire GRAIL to Launch New Era of Cancer Detection | Accelerates Commercialization and Adoption of Transformative Multi-Cancer Screening Test with Potential to Detect More Cancers Earlier and Enable Better Outcomes
Adds Multi-Disciplinary Team and Capabilities Harnessing the Power of Next-Ge... |
| Jul 2, 2015 | Five things you need to know about prenatal testmaker Natera’s $175M IPO | The company’s revenues grew from $55.2 million in 2013 to $159.3 million in 2014 — quite the increase. This comes largely from sales of the Panorama test – in the first three months of 2015 alone, it sold more than 55,000 of these tests.
Th... |
| Jan 12, 2015 | £15m initiative puts Scotland at forefront of gene-led healthcare | £15m initiative puts Scotland at forefront of gene-led healthcare
12-01-2015
A major investment in gene sequencing technology will secure Scotland’s place as a world leader in a genomics revolution that is set to transform healthcare.
The i... |
| Jan 8, 2015 | Illumina announces AOCC to receive Agricultural Greater Good Initiative | Illumina announces AOCC to receive Agricultural Greater Good Initiative
08-01-2015
Project designed to improve food security in Africa
Illumina, Inc. (NASDAQ: ILMN) announced that the African Orphan Crops Consortium (AOCC) is the 2015 recip... |
| Nov 19, 2014 | bioMérieux/Illumina to co-develop next-gen sequencing for monitoring of bacterial infections | bioMérieux/Illumina to co-develop next-gen sequencing for monitoring of bacterial infections
19-11-2014
bioMérieux, a world leader in the field of in vitro diagnostics, and Illumina (Nasdaq:ILMN), a world leader in genomics, announced they ... |
| Oct 16, 2014 | Illumina Accelerator announces investment in inaugural startup class | Illumina Accelerator announces investment in inaugural startup class
16-10-2014
Initial companies focused on breakthrough applications in therapeutics, agriculture and molecular pathology
Illumina, Inc. (NASDAQ:ILMN) announced the selection... |
| Sep 8, 2014 | Actionable Genome Consortium forms with leaders from world-renowned cancer institutions | Actionable Genome Consortium forms with leaders from world-renowned cancer institutions
08-09-2014
World-renowned cancer centers and Illumina, Inc. today announced the formation of the Actionable Genome Consortium (AGC), an effort to recomm... |
| Aug 21, 2014 | Illumina announces strategic partnerships with AstraZeneca, Janssen and Sanofi | Illumina announces strategic partnerships with AstraZeneca, Janssen and Sanofi
21-08-2014
Illumina Inc. (NASDAQ:ILMN) today announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next... |
| Jul 16, 2014 | llumina acquires Myraqa, a leading IVD and companion diagnostic consulting firm | llumina acquires Myraqa, a leading IVD and companion diagnostic consulting firm
16-07-2014
Illumina, Inc. (NASDAQ:ILMN) today announced that it has acquired Myraqa, a regulatory and quality consulting firm specializing in IVDs, particularly... |
| Jun 30, 2014 | Biomnis, Genoma and Center for Human Genetics Martinsried enter agreements with Illumina | Biomnis, Genoma and Center for Human Genetics Martinsried enter agreements with Illumina
30-06-2014
Illumina, Inc. (NASDAQ:ILMN) today announced that it has entered into separate agreements with Biomnis, Genoma, and the Center for Human Gen... |
| Mar 18, 2014 | Genomic data mining firm hopes to help personalized medicine become commonplace in 3-5 years | He’s the founder of Expanse Bioinformatics, which has been building up a portfolio of algorithms and methodologies that may eventually enable doctors to recommend a course of treatment or a change in behavior to treat or prevent certain dis... |
| Jan 27, 2012 | Illumina launches “poison pill” against Roche’s takeover bid | MassDevice.com On Call | MASSDEVICE ON CALL —Illumina’s (NSDQ:ILMN) board of directors adopted a "poison pill" strategy in response to a hostile takeover bid by Roche (PINK:RHHBY).
Illumina adopted a rights agreement which allows shareholders other than t... |
| Jul 27, 2010 | Illumina Acquires Helixis for Up to $105M, To Get Small, Low-Cost Genetic Analysis Tool | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
San Diego-based Illumina has acquired an intriguing startup from southern California with a vision of putting low-cost genetic analysis systems on every biologist’s benchtop.
... |
| Sep 13, 2007 | Decoding 23andMe — Illumina spills the beans | First, it was self-described 23andMe investor Martin Varsavsky who spilled some early information about the secretive personal-genomics startup founded by Sergey Brin‘s new wife, Anne Wojcicki, and now backed by Google and Genentech. (See o... |
| Genomic data mining firm hopes to help personalized medicine become commonplace in 3-5 years | Charles Eldering started developing methods for mining big data back in the late ’90s on a project that characterized consumers based on their purchasing and television viewing habits. Now, a decade and a half later, similar technology is f... |
| Carl Icahn claims Illumina directors got extra insurance to close ‘disastrous’ $7.1 billion Grail deal | Carl Icahn alleged that Illumina’s directors demanded extra personal liability insurance before the biotech company signed off on a $7.1 billion acquisition of cancer test developer Grail in 2021.
He also alleged the Illumina board decided ... |
| The ex-FDA chief Stephen Hahn says the pandemic taught him the importance of the private sector. He's now the CEO of a new cancer biotech. | Stephen Hahn, then the Food and Drug Administration commissioner, addressing the daily coronavirus task-force briefing on April 21, 2020. Jonathan Ernst/Reuters This story is available exclusively to Insider subscribers. Become an Insider a... |
| Genomics giant Illumina is looking beyond the sequencing box. But investors aren't sold on CEO Francis deSouza's 'legacy-defining' $8 billion gamble. | Illumina's CEO Francis deSouza. Illumina This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Illumina's CEO, Francis deSouza, is moving the gene-sequencing giant into drugs and diagnostics.
T... |
| Illumina unveils plans to cut costs as it faces shrinking margins | Illumina unveiled plans to cut costs as it faces shrinking margins
The plans aim to reduce Illumina’s annualized run rate expenses by more than $100 million starting later this year, according to the company’s first-quarter earnings release... |
| Illumina hit with record $476 million fine for closing Grail deal without EU approval | European Union regulators fined Illumina a record 432 million euros ($476 million) for closing its acquisition of cancer test developer Grail without first securing regulatory approval.
A spokesperson for San Diego-based Illumina told CNBC ... |
| Stocks roar back from 2022 low, S&P 500 on track for best 2-day gain in 2 years | Stocks surged Tuesday as Wall Street built on a sharp rally seen in the previous session and bond yields continued to fall.
The Dow Jones Industrial Average rose 581 points, or 1.97%. The S&P 500 added 2.09%, and the Nasdaq Composite wa... |
| Illumina to acquire early cancer detection startup Grail for $8B | A startup focused on early detection of cancer that was spun out of one of the largest genetic analysis companies three years ago is now being acquired by the latter.
On Monday, San Diego-based Illumina said it would acquire Menlo Park, Cal... |
| Five things you need to know about prenatal testmaker Natera’s $175M IPO | California genetic testmaker Natera just upped its IPO target from $100 million to $175 million and begins trading today, opening at $18 per share. Its ticker symbol on the Nasdaq is “NTRA.”
The company’s lead product is its Panorama test. ... |
| Ginkgo Bioworks CEO on scaling up Covid-19 testing: ‘If we try, we can win’ | Ginkgo Bioworks is hoping to help scale up Covid-19 testing.
The company’s CEO is optimistic that the company can produce a half million tests per day.
It is hoping to get approval later this summer.
The start-up made CNBC’s 2020 Disruptor ... |
| SEC investigating Illumina over acquisition of cancer test developer Grail | The U.S. Securities and Exchange Commission is investigating Illumina over its controversial $7.1 billion acquisition of cancer test developer Grail.
Illumina said it is cooperating with the SEC.
The Grail deal has also faced heavy scrutiny... |
| Illumina shareholders oust board chair, CEO survives Carl Icahn proxy battle | Illumina shareholders ousted board chairman John Thompson.
Carl Icahn had urged shareholders to oust both Thompson and CEO Francis deSouza. DeSouza survived the fight.
An Illumina spokesperson said a new board chair will be chosen in the ne... |
| Carl Icahn calls Illumina Q1 results ‘very disappointing,’ slams cost-cutting plan | Carl Icahn called the first-quarter results of Illumina “very disappointing.”
The activist investor slammed the DNA sequencing company’s new plans to cut costs.
Icahn accused Illumina CEO Francis deSouza of trying to downplay the company’s ... |
| Illumina announces CEO transition plan as Francis deSouza resigns | Illumina on Sunday announced its board of directors has accepted the resignation of CEO Francis deSouza.
His resignation came just weeks after activist investor Carl Icahn failed to oust him from the biotech company.
Charles Dadswell, Illum... |
| Stocks making the biggest moves midday: Twitter, Poshmark, Rivian and more | Check out the companies making headlines in midday trading.
Twitter — Shares of Twitter surged nearly 13% after a report that Elon Musk plans to go through with the acquisition of the company at $54.20 per share, the originally agreed-upon ... |